[Form 3] NewcelX Ltd. Initial Statement of Beneficial Ownership
Rhea-AI Filing Summary
NewcelX Ltd. director Samuel Olivier reported his initial beneficial ownership of stock options in the company. He holds options to purchase 9,117 and 13,676 ordinary shares, each with an exercise price of $7.6200 and expirations on November 4, 2035 and November 27, 2035.
According to the footnotes, as of this filing, options over 759 and 1,139 ordinary shares are already vested and exercisable. The remaining options vest in 11 equal quarterly installments beginning on May 4, 2026, subject to Olivier’s continued service with the company.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Samuel Olivier
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Option to Purchase Ordinary Shares | -- | -- | -- |
| holding | Option to Purchase Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Option to Purchase Ordinary Shares — 22,793 shares (Direct)
Footnotes (2)
- F1. As of the date of this Form 3, options to purchase 759 ordinary shares are vested and currently exercisable. The remaining options vest and become exercisable beginning on May 4, 2026 in 11 equal installments on a quarterly basis, subject to the Reporting Person's continued service.
- F2. As of the date of this Form 3, options to purchase 1,139 ordinary shares are vested and currently exercisable. The remaining options vest and become exercisable beginning on May 4, 2026 in 11 equal installments on a quarterly basis, subject to the Reporting Person's continued service.
AI-generated analysis. How Rhea-AI works. Not financial advice.